A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects

Kunming Pharmaceuticals, Inc.1 个研究点分布在 1 个国家目标入组 54 人开始时间: 2026年3月1日最近更新: 2026年2月19日

适应症

干预措施

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 54
试验地点: 1
主要终点: Adverse Events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a single-center, double-blind study to evaluate the safety, tolerability, pharmacokinetics of Gastrodin Injection in healthy Subjects

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Subjects must have a full understanding of the trial's purpose, nature, procedures, and potential adverse reactions, voluntarily consent to participate as subjects, sign the informed consent form prior to the initiation of any research procedures, be capable of effective communication with investigators, and understand and comply with all requirements of the study.
•Healthy male or female subjects aged 18 to 65 years (inclusive of boundary values), with a male-to-female ratio of 1:
•Male subjects with a body weight ≥ 50.0 kg and female subjects with a body weight ≥ 45.0 kg. body mass index (BMI) ranging from 19.0 to 26.0 kg/m² (inclusive of boundary values) .
•Subjects must have no fertility plans during the trial period and within 3 months after the final administration, voluntarily adopt effective contraceptive measures, and have no plans to donate sperm or eggs.

排除标准

•Subjects who developed acute diseases within 2 weeks prior to screening, such as acute gastroenteritis, acute upper respiratory tract infection, acute appendicitis, etc.
•Subjects with a history of any clinically severe diseases or conditions that the investigator deems may interfere with the evaluation of the safety or pharmacokinetic properties of the investigational drug, including but not limited to diseases of the circulatory, respiratory, endocrine, nervous, digestive, urinary systems, as well as hematological, immunological, psychiatric, and metabolic diseases.
•Subjects who underwent major surgery within 6 months prior to screening, or plan to undergo surgery during the study period or within 1 month after the trial completion.
•Subjects with an allergic diathesis (known hypersensitivity to two or more drugs) or known hypersensitivity to Gastrodin Injection and its related excipients.
•Subjects who donated blood within 3 months prior to screening, lost a total of ≥ 400 mL of blood due to blood donation or other causes (excluding normal menstrual blood loss in females) within 6 months prior to screening, or have a history of unexplained abnormal bleeding .
•Subjects who cannot tolerate venipuncture, indwelling needles or have a history of trypanophobia or hematophobia.
•Subjects with special dietary requirements who are unable to comply with the unified diet.
•Subjects who participated in other clinical trials and received investigational drugs or devices within 3 months prior to screening (Note: The end time is defined as the date of the last visit for trial discharge).
•Subjects who received live attenuated vaccine within 2 weeks prior to screening or require live attenuated vaccine during the trial period.
•Subjects who used any medications (including prescription drugs, nonprescription drugs, and Chinese herbal medicines) within 2 weeks prior to screening; Subjects who have consumed strong tea, beverages containing caffeine or alcohol or pomelos, grapefruits and their juices which affect drug metabolism, within 48 hours prior to screening.
•Subjects with an average daily cigarette consumption of more than 5 cigarettes within 3 months prior to screening, or those who cannot discontinue the use of any tobacco products during the trial period.
•Subjects with a history of drug abuse (including non-medical use of various narcotic drugs and psychotropic substances) in the past year, or those with positive results in drug abuse screening (including morphine, methamphetamine, ketamine, ecstasy, tetrahydrocannabinolic acid).
•Subjects with alcoholism, or those who consumed alcohol frequently within 6 months prior to screening (specifically: >14 units per week. 1 unit = 360 mL of beer, 150 mL of wine, or 45 mL of baijiu), or those with a positive alcohol breath test result at screening, or those who cannot abstain from alcohol during the trial period.
•Subjects with clinically significant abnormalities in vital signs assessment, physical examination, chest X-ray (posteroanterior view), clinical laboratory tests (complete blood count, urinalysis, blood biochemistry, coagulation function), and 12-lead electrocardiogram.
•Subjects with positive results in any item of infectious disease screening during the screening period (including hepatitis B surface antigen, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus antibody, syphilis antibody).
•Other subjects deemed unsuitable for participation by the investigator.
•Female subjects should also be excluded if they meet the following conditions in addition to the above requirements:
•Those who have had unprotected sexual intercourse with their partners within 14 days before screening.
•Women with positive pregnancy test results or those who are lactating.
•Women whose menstrual period is expected to occur during the drug administration and safety observation period.